• 1
    Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417422.
  • 2
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 10981105.
  • 3
    Schalm SW, de Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995; 22 (suppl): 52S56S.
  • 4
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 10991105.
  • 5
    Swartz MN. Mitochondrial toxicity-new adverse drug effects. N Engl J Med 1995; 333: 11461148.
  • 6
    Colacino JM, Malcolm SK, Jaskunas SR. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 1994; 38: 19972002.
  • 7
    Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of l-(2-deoxy-2-fluoro-l-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555563.
  • 8
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84958499.
  • 9
    de Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Staley H. A dose ranging study to determine the antiviral activity and safety of lamivudine (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection [Abstract]. Gut 1993; 34: (Suppl) 5SA.
  • 10
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 11
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 12
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131520.
  • 13
    Rademakers LH, Cleton MI, Kooijman C, de la Faille H Baart, van Hattum J. Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment Hepatology 1990; 11: 449457.
  • 14
    Lauterburg BH, Liang D, Schwarzenbach FA, Breen KJ. Mitochondrial dysfunction in alcoholic patients as assessed by breath analysis. Hepatology 1993; 17: 418422.
  • 15
    De Vries DD, Went LL, Bruyn GW, Scholte HR, Hofstra RMW, Bolhuis PA, van Oost B. Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet 1996; 58: 703711.
  • 16
    Lehman TC, Hale DE, Bhala A, Thorpe C. An acyl-coenzyme A dehydrogenase assay utilizing the ferricenium ion. Anal Biochem 1990; 186: 280284.
  • 17
    Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP. Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1995; 1271: 7583.
  • 18
    Kornberg A. Lactic dehydrogenase of muscle. Methods Enzymol 1955; 1: 441443.
  • 19
    Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE, Van't Veer-Korthof ET, Van der Harten JJ, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci 1983; 62: 327355.
  • 20
    Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 1977; 60: 716723.
  • 21
    Honkoop P, de Man RA, Zondervan PE, Niesters HGM, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine is associated with a decrease in HBV-DNA by PCR. Hepatology 1995; 22: 328.
  • 22
    Michaletz PA, Cap L, Alpert E, Lauterburg BH. Assessment of mitochondrial function in vivo with a breath test utilizing alpha-ketoisocaproic acid. Hepatology 1989; 10: 829832.
  • 23
    Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989; 264: 1193411937.
  • 24
    Walker JE. The NADH: ubiquinone oxidoreductase (Complex I) of respiratory chains. Q Rev Biophys 1992; 25: 253324.
  • 25
    Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 1985; 54: 10151069.
  • 26
    Lau JY, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJ, Williams R. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956962.
  • 27
    Nevens F, Tyrell DL, de Man RA, Main J, Beranek P, Sidar S, Fevery J, et al. A six months dose ranging study of the safety and efficacy of lamivudine in chronic hepatitis B. J Hepatol 1995; 23: (Suppl 1) 91S.